Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi JT - don’t think rennaps will be hanging around.......might bump into another pigeon ??
The only same old I see are disgruntled aim lost all my pot but still hanging around posters. There is a commercialised compound with a 5m milestone coming. Partnered with the icr the leading cancer research org globally with more commercialised compounds than any big pharma. A route to fast track approval after phase2. An.orphan indication with poor life expectancy and a likely nod from the fda to be on sale. That's 10 p. Other indications upwards. Plus tyk2. Feel free to YAWN. If that is the sum of your contribution of course you will remain here in ten years. Yawning.
Hi All - There was another article posted by Endpoints today. This article refers to the *gene therapy field
as sizzling*
https://endpts.com/cue-the-ma-chatter-uniqure-is-scouting-for-a-buyout-deal-as-gene-therapy-field-sizzles-report/
Highlights
*the business news service states that uniQure has brought in advisers to see what might be done — including a sale — *
sounds familiar to our NEDs and I'm sure as well as AIM compliance (could have used any NED), SAR chose industry relevant NEDs
*pharma giants now prowling the clinical players for partners and acquisitions*.
John Carroll closed by saying *Just how hot is gene therapy in the deal world these days? We’ll take an in-depth look at the numbers for you early Monday*
GLA
This deal is I believe mainly cancer driven. Pfizer massive and still have more than enough cash to do many more deals like this. Sareum are still hot in auto-immune ane Pfizer knows that first hand as they been trialling their marketed $1.8bn incomed Tofa against Tyk2 which smashed it in trials and is more selective and they know it- so they will no doubt want it. Furhermore for our Tyk2 cancer and Lupus Pfizer are up against Astrazeneca, Roche, Gsk to name a few who are probably more focused on cancer deals.
I think there is some uncertainty as to whether the Nimbus Tyk2 may come back on the market
https://endpts.com/ftc-demands-more-info-from-bristol-myers-celgene-on-psoriasis-drugs-signaling-a-potential-hitch-for-74b-deal/
I dont think it will be long now to find out. another overlapping drug in the dealgot dropped back today
https://endpts.com/as-bristol-myers-celgene-tie-up-loose-ends-beigene-pockets-150m-from-pd-1-breakup/
So I dont think we will get a deal until the landscape is settled, but that may be very soon. GLA
Array are a lot bigger than SAR - 3 Approved drugs plus another 8 in Phase 3 trials and a further 5 in Phase 1/2. They would have been a much bigger blip on the Pfizer radar than SAR is currently. However, because Pfizer have 'waited' to take them out they've had to pay a very high price. Depends on Pfizers appetite for risk as to whether SAR would be a target and at what price. Still, its nice to see activity in this field.
Dr. Zed, why not us? What's we have missed? Or the data it's not enough to show them, "hey we're here and we're good"
Pfizer to Acquire Array BioPharma —Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term —Opportunity to strengthen category leadership in Oncology with the addition of a breakthrough combination of BRAF/MEK inhibitors under investigation for a potential first-in-class therapy for patients with BRAF-mutant metastatic colorectal cancer —Expands Pfizer’s pipeline with multiple high-potential targeted investigational cancer therapies and adds a large portfolio of royalty-generating out-licensed medicines —Plans to maintain highly productive research unit in Boulder to complement Pfizer’s research hubs —Transaction valued at $48 per Array share in cash, for a total enterprise value of approximately $11.4 billion June 17, 2019 06:45 AM Eastern Daylight Time NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have approved the merger. “We are very excited by Array’s impressive track record of successfully discovering and developing innovative small-molecules and targeted cancer therapies” Tweet this Array’s portfolio includes the approved combined use of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the treatment of BRAFV600E or BRAFV600K mutant unresectable or metastatic melanoma. The combination therapy has significant potential for long-term growth via expansion into additional areas of unmet need and is currently being investigated in over 30 clinical trials across several solid tumor indications, including the Phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer (mCRC). In the U.S., colorectal cancer is the third most common type of cancer in men and women. An estimated 140,250 patients were diagnosed with cancer of the colon or rectum in 2018, and approximately 50,000 are estimated to die of their disease each year.1 BRAF mutations are estimated to occur in up to 15% of colorectal cancer cases and represent a poor prognosis for these patients. “Today’s announcement reinforces our commitment to deploy our capital to bring breakthroughs that change patients’ lives while creating shareholder value,” said Albert Bourla, chief executive officer of Pfizer. “The proposed acquisition of Array strengthens our innovative biopharmaceutical business, is expect